<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2678443-A1" country="EP" doc-number="2678443" kind="A1" date="20140101" family-id="44279774" file-reference-id="311173" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146551624" ucid="EP-2678443-A1"><document-id><country>EP</country><doc-number>2678443</doc-number><kind>A1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12709012-A" is-representative="NO"><document-id mxw-id="PAPP154825547" load-source="docdb" format="epo"><country>EP</country><doc-number>12709012</doc-number><kind>A</kind><date>20120220</date><lang>EN</lang></document-id><document-id mxw-id="PAPP168045664" load-source="docdb" format="original"><country>EP</country><doc-number>12709012.4</doc-number><date>20120220</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140454508" ucid="EP-11155178-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>11155178</doc-number><kind>A</kind><date>20110221</date></document-id></priority-claim><priority-claim mxw-id="PPC140449573" ucid="EP-12709012-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>12709012</doc-number><kind>A</kind><date>20120220</date></document-id></priority-claim><priority-claim mxw-id="PPC140445230" ucid="EP-2012000833-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>2012000833</doc-number><kind>W</kind><date>20120220</date></document-id></priority-claim><priority-claim mxw-id="PPC140448333" ucid="US-201261588975-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201261588975</doc-number><kind>P</kind><date>20120120</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988128400" load-source="docdb">C12Q   1/68        20060101AFI20120914BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1967036547" load-source="docdb" scheme="CPC">C12Q   1/6851      20130101 LI20160225BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1967039710" load-source="docdb" scheme="CPC">C12Q   1/6888      20130101 LI20160225BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1967043155" load-source="docdb" scheme="CPC">C12Q2600/16        20130101 LA20160225BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1967043372" load-source="docdb" scheme="CPC">C12Q2600/166       20130101 LA20160225BHEP        </classification-cpc><classification-cpc mxw-id="PCL2081251418" load-source="docdb" scheme="CPC">C12Q   1/6879      20130101 FI20140529BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132187356" lang="DE" load-source="patent-office">VERFAHREN ZUR QUANTIFIZIERUNG MENSCHLICHER DNA MITTELS EINER INTERNEN STEUERUNG</invention-title><invention-title mxw-id="PT132187357" lang="EN" load-source="patent-office">METHOD FOR QUANTIFYING HUMAN DNA USING AN INTERNAL CONTROL</invention-title><invention-title mxw-id="PT132187358" lang="FR" load-source="patent-office">PROCÉDÉ DE QUANTIFICATION D'ADN HUMAIN AU MOYEN D'UN TÉMOIN INTERNE</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR918160243" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>QIAGEN GMBH</last-name><address><country>DE</country></address></addressbook></applicant><applicant mxw-id="PPAR918163679" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>QIAGEN GMBH</last-name></addressbook></applicant><applicant mxw-id="PPAR918982756" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Qiagen GmbH</last-name><iid>100779135</iid><address><street>Qiagen Strasse 1</street><city>40724 Hilden</city><country>DE</country></address></addressbook></applicant><applicant mxw-id="PPAR918153976" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>QIAGEN MANCHESTER LTD</last-name><address><country>GB</country></address></addressbook></applicant><applicant mxw-id="PPAR918162092" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>QIAGEN MANCHESTER LIMITED</last-name></addressbook></applicant><applicant mxw-id="PPAR918983018" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>QIAGEN Manchester Limited</last-name><iid>101213754</iid><address><street>Skelton House Lloyd Street North</street><city>MANCHESTER M15 6SH</city><country>GB</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918144256" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>DI PASQUALE FRANCESCA</last-name><address><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR918173293" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>DI PASQUALE, FRANCESCA</last-name></addressbook></inventor><inventor mxw-id="PPAR918985273" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>DI PASQUALE, FRANCESCA</last-name><address><street>Derendorfer Strasse 70</street><city>40479 Düsseldorf</city><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR918151195" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>ENGEL HOLGER</last-name><address><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR918158457" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>ENGEL, HOLGER</last-name></addressbook></inventor><inventor mxw-id="PPAR918982838" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>ENGEL, HOLGER</last-name><address><street>Käthe-Kollwitz-Weg 5</street><city>40724 Hilden</city><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR1149603169" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>STRAUSS SASCHA</last-name><address><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR1149603168" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>STRAUß, Sascha</last-name></addressbook></inventor><inventor mxw-id="PPAR918988147" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>STRAU, SASCHA</last-name><address><street>Bahnstraße 8-10</street><city>42697 Solingen</city><country>DE</country></address></addressbook></inventor><inventor mxw-id="PPAR918162437" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>THELWELL NICOLA JO</last-name><address><country>GB</country></address></addressbook></inventor><inventor mxw-id="PPAR918158380" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>THELWELL, NICOLA, JO</last-name></addressbook></inventor><inventor mxw-id="PPAR918993641" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>THELWELL, NICOLA, JO</last-name><address><street>21 Norfolk Street</street><city>Glossop Derbyshire SK13 7QU</city><country>GB</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918992251" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Fanelli Haag Kilger PLLC</last-name><iid>101309309</iid><address><street>Fasanenstrasse 29</street><city>10719 Berlin</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="EP-2012000833-W"><document-id><country>EP</country><doc-number>2012000833</doc-number><kind>W</kind><date>20120220</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012113577-A1"><document-id><country>WO</country><doc-number>2012113577</doc-number><kind>A1</kind><date>20120830</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548938150" load-source="docdb">AL</country><country mxw-id="DS548868717" load-source="docdb">AT</country><country mxw-id="DS548839603" load-source="docdb">BE</country><country mxw-id="DS548937241" load-source="docdb">BG</country><country mxw-id="DS548933633" load-source="docdb">CH</country><country mxw-id="DS548839604" load-source="docdb">CY</country><country mxw-id="DS548945024" load-source="docdb">CZ</country><country mxw-id="DS548938151" load-source="docdb">DE</country><country mxw-id="DS548839605" load-source="docdb">DK</country><country mxw-id="DS548839606" load-source="docdb">EE</country><country mxw-id="DS548921192" load-source="docdb">ES</country><country mxw-id="DS548937242" load-source="docdb">FI</country><country mxw-id="DS548937243" load-source="docdb">FR</country><country mxw-id="DS548938152" load-source="docdb">GB</country><country mxw-id="DS548839607" load-source="docdb">GR</country><country mxw-id="DS548938153" load-source="docdb">HR</country><country mxw-id="DS548945025" load-source="docdb">HU</country><country mxw-id="DS548933638" load-source="docdb">IE</country><country mxw-id="DS548839608" load-source="docdb">IS</country><country mxw-id="DS548937244" load-source="docdb">IT</country><country mxw-id="DS548839609" load-source="docdb">LI</country><country mxw-id="DS548937245" load-source="docdb">LT</country><country mxw-id="DS548868766" load-source="docdb">LU</country><country mxw-id="DS548937246" load-source="docdb">LV</country><country mxw-id="DS548937247" load-source="docdb">MC</country><country mxw-id="DS548868767" load-source="docdb">MK</country><country mxw-id="DS548868768" load-source="docdb">MT</country><country mxw-id="DS548868769" load-source="docdb">NL</country><country mxw-id="DS548945030" load-source="docdb">NO</country><country mxw-id="DS548868770" load-source="docdb">PL</country><country mxw-id="DS548839610" load-source="docdb">PT</country><country mxw-id="DS548817792" load-source="docdb">RO</country><country mxw-id="DS548839611" load-source="docdb">RS</country><country mxw-id="DS548868771" load-source="docdb">SE</country><country mxw-id="DS548938158" load-source="docdb">SI</country><country mxw-id="DS548945031" load-source="docdb">SK</country><country mxw-id="DS548945032" load-source="docdb">SM</country><country mxw-id="DS548921193" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99626080" ref-ucid="WO-2012113577-A1" lang="EN" load-source="patent-office"><p num="0000">The present invention relates to a method for quantifying and/or detecting one or more nucleic acids of a genome in a sample, wherein in an amplification reaction, (i) a first nucleic acid is amplified, the locus that is amplified is a multicopy locus (MCL) within the genome, wherein the locus shares at least 80 % sequence identity to a sequence according to SEQ ID NO. 1 over a stretch of 80 base pairs, and wherein the multicopy locus has copies on at least two different chromosomes, (ii) a second nucleic acid that has been added as an internal control (IC) is also amplified, and (iii) the amount of amplification product from the amplification of the first nucleic acid is determined.</p></abstract><abstract mxw-id="PA99824599" ref-ucid="WO-2012113577-A1" lang="EN" source="national office" load-source="docdb"><p>The present invention relates to a method for quantifying and/or detecting one or more nucleic acids of a genome in a sample, wherein in an amplification reaction, (i) a first nucleic acid is amplified, the locus that is amplified is a multicopy locus (MCL) within the genome, wherein the locus shares at least 80 % sequence identity to a sequence according to SEQ ID NO. 1 over a stretch of 80 base pairs, and wherein the multicopy locus has copies on at least two different chromosomes, (ii) a second nucleic acid that has been added as an internal control (IC) is also amplified, and (iii) the amount of amplification product from the amplification of the first nucleic acid is determined.</p></abstract><abstract mxw-id="PA99626081" ref-ucid="WO-2012113577-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne un procédé pour quantifier et/ou détecter un ou plusieurs acides nucléiques d'un génome dans un échantillon, dans lequel, dans une réaction d'amplification, (i) un premier acide nucléique est amplifié, le locus qui est amplifié étant un locus multicopies (MCL) à l'intérieur du génome, le locus partageant une identité de séquence d'au moins 80 % avec une séquence conforme à SEQ ID NO. 1 sur une étendue de 80 paires de bases, et le locus multicopies ayant des copies sur au moins deux chromosomes différents, (ii) un deuxième acide nucléique qui a été ajouté comme témoin interne (IC) est également amplifié, et (iii) la quantité de produit d'amplification issu de l'amplification du premier acide nucléique est déterminée.</p></abstract><abstract mxw-id="PA99824600" ref-ucid="WO-2012113577-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne un procédé pour quantifier et/ou détecter un ou plusieurs acides nucléiques d'un génome dans un échantillon, dans lequel, dans une réaction d'amplification, (i) un premier acide nucléique est amplifié, le locus qui est amplifié étant un locus multicopies (MCL) à l'intérieur du génome, le locus partageant une identité de séquence d'au moins 80 % avec une séquence conforme à SEQ ID NO. 1 sur une étendue de 80 paires de bases, et le locus multicopies ayant des copies sur au moins deux chromosomes différents, (ii) un deuxième acide nucléique qui a été ajouté comme témoin interne (IC) est également amplifié, et (iii) la quantité de produit d'amplification issu de l'amplification du premier acide nucléique est déterminée.</p></abstract><description mxw-id="PDES50931496" ref-ucid="WO-2012113577-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> METHOD FOR QUANTIFYING HUMAN DNA USING AN INTERNAL CONTROL </p><p id="p0002" num="0002">Field of the Invention </p><p id="p0003" num="0003">The present invention is in the field of molecular biology, diagnostics, more particularly in the field of analytical and forensic sciences. The invention is further in the field of nucleic acid amplification and quantification, more particularly in the field of DNA quantification. Moreover, the early assessment of the presence of different contributors in a DNA stain is often a very important piece of information during an investigation. In this case, the STR analysis will result difficult because of the interference of the multiple contributors. </p><p id="p0004" num="0004">A particular case of a mixed sample is the sexual assault stain containing a mixture of female and male DNA. The accurate determination of the male: female DNA ratio helps in the selection of the optimal downstream STR analysis. In the case of a very low amount of available offender DNA a particular type of STR analysis can be carried out addressing genetic elements present exclusively on the Y-chromosome, thus excluding the interference of the female contribution. Background </p><p id="p0005" num="0005">The determination of the quantity of DNA recovered from forensic samples as well as other samples is a critical step in the over all DNA typing process, but also in the detection of DNA in various other fields of science. A narrow range of input DNA from 0.5 to 2 ng is often needed to produce optimal results with for example multiplex DNA typing kits. Therefore, in order to ensure that a positive result is a positive result and/or a negative result is a negative result due to the absence of DNA, quantification of DNA is of absolute importance. Furthermore, the quality of standards for forensic DNA testing laboratories requires human- specific DNA quantification. This is due to isolation techniques that can recover human DNA as well as bacterial and other exogenous DNA. A number of procedures have been developed to permit quantification of human-specific DNA including start-blot techniques, liquid based hybridization assays and real-time PCR (polymerase chain reaction). Currently, real-time PCR is the dominant technique due to its wide dynamic range and ease of automation. 
<!-- EPO <DP n="3"/>-->
 The modern STR-Kits have become much more sensitive and can obtain good results even using low amounts of DNA. Therefore, there is a desire for a method, kit and nucleic acid region that allows precise and accurate quantification of human DNA even in low concentrated samples. There are certain quantification and detection kits already available, however, these have serious drawbacks. One such kit is the Quantifiler Human Kit (Applied Biosystems) another kit is Quantifiler Duo Kit (Applied Biosystems) another kit is the Plexor HY Real-Time PCR Quantification Kit (Promega). Both the Quantifiler Duo Kit and the Plexor HY Kit target an autosomal and a gonosomal (Y-chromosome) target on the genome. Drawbacks for the kits: According to LaSalle et al., (Forensic Science International: Genetics, "Analysis of Single and Multi-copy Methods for DNA Quantification by Real-Time Polymerase Chain Reaction") the Quantifiler Kits are more accurate in the quantification but have a lower dynamic range as the Plexor HY. The Plexor HY offers a higher dynamic range due to the amplification of a multicopy target, but a lower accuracy. This lower accuracy can be attributed to the multicopy target. If less than the full set of 20 copies on a genome amplify, because of, for example, instability in the target copy number, than the ratio between the amplification between autosomal and gonosomal (Y) target may vary. The dynamic range of the Plexor HY kit is slightly better than that of the other kit (LaSalle et al., Forensic Science International: Genetics, "Analysis of Single and Multi-copy Methods for DNA Quantification by Real-Time Polymerase Chain Reaction"). In a statistical comparison LaSalle et al. demonstrated a significant difference between the two kits. </p><p id="p0006" num="0006">Another important parameter in forensics is the degradation grade of the DNA that has to be analyzed. Since the amplicon size of the Quantifiler Human and Plexor HY vary from 62 to 133 base pairs (bp), significant differences might be expected when the kits are applied to degraded DNA. Also, inhibitors must be taken into account. It may well be that DNA is present in the reaction no result is obtained due to the presence of inhibitory substances. </p><p id="p0007" num="0007">Summary of the Invention </p><p id="p0008" num="0008">The present invention solves the above identified problem and provides for the following solution as outlined below. 
<!-- EPO <DP n="4"/>-->
 The invention relates to a method for quantifying and/or detecting one or more nucleic acids of a genome in a sample, wherein in an amplification reaction, (a) a first nucleic acid is amplified, the locus that is amplified is a multicopy locus (MCL) within the genome, wherein the locus shares at least 80 % sequence identity to a sequence according to SEQ ID NO. 1 over a stretch of 80 base pairs, and wherein, the multicopy locus has copies on at least two different chromosomes, (b) a second nucleic acid that has been added as an internal control is also amplified, and (c) the amount of amplification product from the amplification of the first nucleic acid is determined. The invention also relates to a primer and primer pair for amplifying the first nucleic acid (MCL). </p><p id="p0009" num="0009"> Further, the invention relates to a primer and primer pair for amplifying the second nucleic acid (IC). </p><p id="p0010" num="0010"> Further, the invention relates to a primer and primer pair for amplifying the third nucleic acid (MCL-Y) </p><p id="p0011" num="0011"> These may be in a kit. Hence, the invention also relates to a kit for detecting and/or quantifying human nucleic acids </p><p id="p0012" num="0012">Herein, the first nucleic acid is a multicopy locus as outlined in more detail below and often referred to as "MCL". </p><p id="p0013" num="0013">Herein, the second nucleic acid is an internal control as outlined in more detail below and is often referred to as "IC". Herein, the third nucleic acid is a multicopy locus on the Y-chromosome as outlined in more detail below and is often referred to as "MCL-Y". </p><p id="p0014" num="0014">Detailed description of the Invention As outlined above the quantification and detection of human DNA is difficult. Often, inhibitory substances lead to a negative PCR result, even though an adequate amount of DNA for amplification would actually be present in the sample. 
<!-- EPO <DP n="5"/>-->
 The present invention solves this problem. It relates to a method for quantifying and/or detecting one or more nucleic acids of a genome in a sample, wherein in an amplification reaction, (a) a first nucleic acid is amplified, the locus that is amplified is a multicopy locus (MCL) within the genome, wherein the locus shares at least 80 % sequence identity to a sequence according to SEQ ID NO. 1 over a stretch of 80 base pairs, and wherein, the multicopy locus has copies on at least two different chromosomes, (b) a second nucleic acid that has been added as an internal control is also amplified, and (c) the amount of amplification product from the amplification of the first nucleic acid is determined. Astonishingly, the inventors have found that multicopy loci that are not a repetitive element are superior to other loci when used for detection and/or quantification of nucleic acids. It is well known, that repetitive elements may vary in copy number between individuals. In general, these nucleic acids may have any origin, prokaryotic, eukaryotic or the like. Preferably they are mammalian and more preferably human. This is because one great advantage of the present invention is its application in the field of forensics. </p><p id="p0015" num="0015">One such sequence is identified in SEQ ID NO. 1. The inventors have astonishingly found that this sequence and/or sequences that share sequence similarity with it may be found many times in the human genome. </p><p id="p0016" num="0016">The sequences distributed throughout the genome are not all exactly identical. It is important that the selected primers bind also to the nearly identical sequences. Thus, ideally the locus shares at least 60 %, 70 %, 80 %, 90 % or even 95 % or 98 % sequence identity to a sequence according to SEQ ID NO. 1 over a stretch of 80 base pairs. </p><p id="p0017" num="0017">The determination of percent identity between two sequences is accomplished using the mathematical algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA (1993) 90: 5873- 5877). Such an algorithm is the basis of the BLASTN and BLASTP programs of Altschul et al. (J. Mol. Biol. (1990) 215: 403-410). BLAST nucleotide searches are performed with the BLASTN program, score = 100, word length = 12, to obtain nucleotide sequences homologous SEQ ID NO. 1. To obtain gapped alignments for comparative purposes, Gapped BLAST is utilized as described by Altschul et al. (Nucleic Acids Res. (1997) 25: 3389-3402). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs are used. 
<!-- EPO <DP n="6"/>-->
 It is an aspect of the invention that multiple copies are amplified. Ideally, at least 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 copies on various chromosomes are amplified. SEQ ID NO. 1 or sequences very similar thereto are present 29 times in the human genome. This is not just astonishing but provides for the power of the present method. Also, the copies may be found on various chromosomes such as 1 , 4, 5, 7, 1 1 , 16. </p><p id="p0018" num="0018">It is important to note, that SEQ ID NO. 1 like sequences as defined herein and/or SEQ ID NO. 15 like sequences as defined herein may be used in the method according to the invention. The preferred embodiments outlined below for the method using the SEQ ID NO. 1 sequence all apply likewise to the SEQ ID NO. 15 sequence. Preferably they are used together in one method. </p><p id="p0019" num="0019">Multi-copy locus on the Y-chromosome: </p><p id="p0020" num="0020">Astonishingly, the inventors have also found that multi-copy loci on the Y-chromosome are superior to other loci when used for detection and/or quantification of nucleic acids, because the sensitivity of the reaction can be enhanced. This is because one great advantage of the present invention is its application in the field of forensics. </p><p id="p0021" num="0021">One such sequence is identified in SEQ ID NO. 15. The inventors have astonishingly found that this sequence and/or sequences that share sequence similarity with it may be found many times on the Y-chromosome. </p><p id="p0022" num="0022">The invention relates also to a method for quantifying and/or detecting one or more nucleic acids of a genome in a sample, wherein in an amplification reaction, </p><p id="p0023" num="0023"> a. a first nucleic acid is amplified, the locus that is amplified is a multicopy locus on the Y chromosome (MCL) within the genome, wherein the locus shares at least 80 % sequence identity to a sequence according to SEQ ID NO. 15 over a stretch of 80 base pairs, </p><p id="p0024" num="0024"> b. a second nucleic acid that has been added as an internal control (IC) is also amplified, </p><p id="p0025" num="0025"> c. the amount of amplification product from the amplification of the first nucleic acid is determined. 
<!-- EPO <DP n="7"/>-->
 The sequences distributed throughout the Y-chromosome are not all exactly identical. It is important that the selected primers bind also to the nearly identical sequences. Thus, ideally the locus shares at least 60 %, 70 %, 80 %, 90 % or even 95 % or 98 % sequence identity to a sequence according to SEQ ID NO. 15 over a stretch of 80 base pairs. </p><p id="p0026" num="0026">The forensic workflow of sexual assault samples suggests the quantification of the male DNA before the STR reaction is carried out. This is done first to help in the decision of which kind of STR Kit has to be used for the genetic analysis, and then to determine how much DNA was obtained from a sample, e.g. collected from a crime scene, and how much of this DNA should be used in a STR reaction. Different STR Kits are available, the typical STR Kit detects genetic length polymorphisms on different autosomal chromosomes, but in some cases, such as with sexual assault samples, the analysis of length polymorphisms exclusively on the Y- chromosome could be advantageous, because the female DNA doesn't have a Y chromosome. </p><p id="p0027" num="0027">The typical STR reaction works optimally in certain range of template DNA and the whole analysis is very labor-intensive, therefore methodologies are needed that ensure a very high success rate in the STR analysis. Therefore, it is a real advantage if the quantification kit enables the user not only to surely identify the amount of DNA present but also to assess the absence of inhibitors, which could compromise the STR reaction result, which would result in failure or loss of valuable sample material, which could be further purified in case critical inhibition is observed. </p><p id="p0028" num="0028">Ideally, the amplification product of the third nucleic acid (MCL-Y) is between 60 base pairs and 200 base pairs long, between 80 and 300, between 100 and 200 or between 120 and 180 base pairs. </p><p id="p0029" num="0029">In a preferred embodiment, the third nucleic acid (MCL-Y) is about 130 base pairs in length (+/-20 % ). </p><p id="p0030" num="0030">One feature of the invention is a novel internal control (IC) for detection of PCR inhibitors. The IC is co-amplified in parallel in the same reaction vial with one or more specific targets. The IC is used to detect PCR inhibitors in the reaction. Hence, inhibition of the IC, detectable 
<!-- EPO <DP n="8"/>-->
 by a shift in the threshold cycle in real-time PCR, is a marker for the presence of certain amounts of PCR inhibitors in the reaction. </p><p id="p0031" num="0031">The forensic workflow suggests the quantification of the DNA before the STR reaction is carried out. This is done to determine how much DNA was obtained from a sample, e.g. collected from a crime scene, and how much of this DNA should be used in a STR reaction. The typical STR reaction works optimally in certain range of template DNA and the whole analysis is very labor-intensive, therefore methodologies are needed that ensure a very high success rate in the STR analysis. Therefore, it is a real advantage if the quantification kit enables the user not only to surely identify the amount of DNA present but also to assess the absence of inhibitors, which could compromise the STR reaction result, which would result in failure or loss of valuable sample material, which could be further purified in case critical inhibition is observed. In the present invention, the nature of the IC is astonishingly such that it fits to the recent forensic workflows by reporting the presence of inhibitors, but still giving a good quantification result, providing a stable Ct value of internal control over the whole DNA concentration range when inhibitors are present at uncritical level, and has a high correlation level of inhibitors critical for the STR reaction. Some of the new generation of STR kits recently introduced in the market demonstrate increased inhibitor resistance as kits introduced earlier. These new STR kits have been further developed to provide higher resistance to PCR inhibitors, which also provides new requirements to the DNA quantification methodology, by providing an IC that only reports levels of inhibition that are significant for the success of the subsequent STR reaction. </p><p id="p0032" num="0032">The IC of the present invention carries a control DNA sequence that does not occur in the sample nucleic acid, allowing the selection of oligonucleotide primers and/or probes that specifically only detect the IC. In a preferred embodiment, the IC is a PCR product or a plasmid carrying the control DNA sequence. Alternatively, the IC could also be a synthetic longmer, or a plasmid or any other kind of vector. 
<!-- EPO <DP n="9"/>-->
 In a preferred embodiment also the amount of amplification product of the second nucleic acid is determined. </p><p id="p0033" num="0033">The amplification method is either a non-isothermal method or an isothermal method. </p><p id="p0034" num="0034">The non-isothermal amplification method may be selected from the group of polymerase chain reaction (PCR) (Saiki et al. (1985) Science 230: 1350), quantitative real-time PCR (rtPCR), ligase chain reaction (LCR) (Landegren et al. (1988) Science 241 : 1077-1080). Polymerase chain reaction amplification is preferred. </p><p id="p0035" num="0035">The isothermal amplification method may be selected from the group of helicase-dependent amplification (HDA) (Vincent et al. (2004) EMBO rep 5(8):795-800), thermostable HDA (tHDA) (An et al. (2005) J Biol Chem 280(32):28952-28958), strand displacement amplification (SDA) (Walker et al. (1992) Nucleic Acids Res 20(7): 1691-6), multiple displacement amplification (MDA) (Dean et al. (2002) Proc Natl Acad Sci USA 99(8): 5261 - 5266), rolling-circle amplification (RCA) (Liu et al. (1996) J Am Chem Soc 1 18: 1587-1594), restriction aided RCA (Wang et al. (2004) Genome Res 14:2357-2366), single primer isothermal amplification (SPIA) (Dafforn et al. (2004) Biotechniques 37(5):854-7), transcription mediated amplification (TMA) (Vuorinen et al. (1995) J Clin Microbiol 33: 1856-1859), nicking enzyme amplification reaction (NEAR) (Maples et al. US2009017453), exponential amplification reaction (EXPAR) (Van Ness et al. (2003) Proc Natl Acad Sci USA 100(8):4504-4509), loop mediated isothermal amplification (LAMP) (Notomi et al. (2000) Nucleic Acids Res 28(12):e63), recombinase polymerase amplification (RPA) (Piepenburg et al. (2006) PloS Biol 4(7): 1 1 15-1 120), nucleic acid sequence based amplification (NASBA) (Kievits et al. (1991) J Virol Methods 35:273-286), smart-amplification process (SMAP) (Mitani et al. (2007) Nat Methods 4(3):257-62). </p><p id="p0036" num="0036">By "isothermal amplification reaction" in context of the present invention it is meant that the temperature does not significantly change during the reaction. In a preferred embodiment the temperature of the isothermal amplification reaction does not deviate by more than 10 °C, preferably by not more than 5 °C, even more preferably not more than 2 °C during the main enzymatic reaction step where amplification takes place. </p><p id="p0037" num="0037">Depending on the method of isothermal amplification of nucleic acids different enzymes are 
<!-- EPO <DP n="10"/>-->
 required for the amplification reaction. Known isothermal methods for amplification of nucleic acids are the above mentioned, wherein the at least one mesophilic enzyme for amplifying nucleic acids under isothermal conditions is selected from the group consisting of helicase, mesophilic polymerases, mesophilic polymerases having strand displacement activity, nicking enzymes, recombination proteins, ligases, glycosylases and/or nucleases. </p><p id="p0038" num="0038">"Helicases" are known by those skilled in the art. They are proteins that move directionally along a nucleic acid phosphodiester backbone, separating two annealed nucleic acid strands (e.g. DNA, RNA, or RNA-DNA hybrid) using energy derived from hydrolysis of NTPs or dNTPs. Based on the presence of defined helicase motifs, it is possible to attribute a helicase activity to a given protein. The skilled artisan is able to select suited enzymes with helicase activity for the use in a method according to the present invention. In a preferred embodiment the helicase is selected from the group comprising helicases from different families: superfamily I helicases (e.g. dda, pcrA, F-plasmid tral protein helicase, uvrD), superfamily II helicases (e.g. recQ, NS3-helicase), superfamily III helicases (e.g. AAV rep Helicase), helicases from DnaB-like superfamily (e.g. T7 phage helicase) or helicases from Rho-like superfamily. </p><p id="p0039" num="0039">The amplification methods will comprise buffers, dNTPs or NTPs in addition to the enzymes required. </p><p id="p0040" num="0040">As used herein, the term "dNTP" refers to deoxyribonucleoside triphosphates. Non-limiting examples of such dNTPs are dATP, dGTP, dCTP, dTTP, dUTP, which may also be present in the form of labelled derivatives, for instance comprising a fluorescent label, a radioactive label, a biotin label. dNTPs with modified nucleotide bases are also encompassed, wherein the nucleotide bases are for example hypoxanthine, xanthine, 7-methylguanine, inosine, xanthinosine, 7-methylguanosine, 5,6-dihydrouracil, 5-methylcytosine, pseudouridine, dihydrouridine, 5-methylcytidine. Furthermore, ddNTPs of the above-described molecules are encompassed in the present invention. </p><p id="p0041" num="0041">As used herein, the term "NTP" refers to ribonucleoside triphosphates. Non-limiting examples of such NTPs are ATP, GTP, CTP, TTP, UTP, which may also be present in the form of labelled derivatives, for instance comprising a fluorescent label, a radioactive label, a biotin label. 
<!-- EPO <DP n="11"/>-->
 In a preferred embodiment the amplification method is a polymerase chain reaction or a realtime PCR reaction and the amount of nucleic acid determined, is determined either during the amplification process or as an end point measurement at the end of the amplification reaction. </p><p id="p0042" num="0042">Oligonucleotide primers may be prepared using any suitable method, such as, for example, the phosphotriester and phosphodiester methods or automated embodiments thereof. In one such automated embodiment diethyl phosphoramidites are used as starting materials and may be synthesized as described by Beaucage et al. (1981) Tetrahedron Letters 22: 1859-1862. One method for synthesizing oligonucleotides on a modified solid support is described in US Patent No. 4,458,006. It is also possible to use a primer, which has been isolated from a biological source (such as a restriction endonuclease digest). Preferred primers have a length of about 6-100 bases, more preferably about 20-50, most preferably about 20-40 bases. </p><p id="p0043" num="0043">DNA Quantification using real-time PCR. </p><p id="p0044" num="0044">During PCR, the amount of DNA theoretically doubles with every cycle. After each cycle, the amount of DNA is twice what it was before. </p><p id="p0045" num="0045">The absolute amount of DNA in an unknown sample is preferably determined using the IC. </p><p id="p0046" num="0046">Using real-time PCR techniques, fluorescence is detected and measured in the real-time PCR thermocycler, and its geometric increase corresponding to exponential increase of the product is used to determine the threshold cycle (CT) in each reaction. </p><p id="p0047" num="0047"> A standard curve (plot of CT value/crossing point against log of amount of standard) is generated using different dilutions of the standard. The CT value of the unknown samples is compared with the standard curve, allowing calculation of the initial amount of the target. It is important to select an appropriate standard for the type of nucleic acid to be quantified. To generate a standard curve, at least 5 different amounts of the standard should be quantified, and the amount of unknown target should fall within the range of the standard curve. Hence, in one embodiment also the above quantification steps are performed. </p><p id="p0048" num="0048">Ideally, the amplification product of the first nucleic acid (MCL) is between 60 base pairs and 200 base pairs long, between 80 and 300, between 100 and 200 or between 120 and 180 base pairs. 
<!-- EPO <DP n="12"/>-->
 Further, ideally, the amplification product of the second nucleic acid (IC) is between 60 and 400, between 100 and 400 base pairs, between 80 and 300 base pairs or between 150 and 250 base pairs. Astonishingly it has turned out that, if the amplification of the second nucleic acid (IC) is longer than the amplification product of the first nucleic acid (MCL) better results may be achieved. </p><p id="p0049" num="0049">In a preferred embodiment, the first nucleic acid (MCL) is about 140 base pairs in length (+/- 20 %) and the second nucleic acid (IC) is about 200 base pairs in length (+/- 20 %). </p><p id="p0050" num="0050">In a preferred embodiment, the third nucleic acid (MCL-Y) is about 130 base pairs in length (+/-20 % ). Ideally, the amplification reaction comprises, (i) Tris-HCl at a pH of between 8 and 8.8 (at 20°C) and/or, (ii) potassium salt selected from the group of, potassium chloride and potassium sulphate and/or, (iii) an ammonium salt, preferably ammonium chloride or ammonium sulphate and/or, (vi) magnesium chloride and/or, (v) a hot-start polymerase. Preferably, the concentration of Tris-HCl is in the range from 10 to 100 mM, most preferably in the range from 20 to 70 mM, the concentration of K<sup>+</sup> is in the range from 1-25 mM, most preferred in the range from 2,5 to 20 mM, the concentration of NH<sub>4</sub><sup>+</sup> in range from 1 to 40 mM, most preferred in the range from 2,5 to 30 mM, and a concentration of Mg<sup>2+</sup> of 0,5 mM to 8 mM in excess to the concentration of the four dNTP's, most preferred a concentration of Mg of 0,7 mM to 5 mM in excess to the concentration of the four dNTP's, a hot-start polymerase, preferentially a hot-start polymerase allowing a hot-start time of less than 5 min, most preferred below 2 min. </p><p id="p0051" num="0051">It is important that the amount of second nucleic acid is correctly chosen. This IC is able to determine whether there is DNA in the reaction or whether possibly no reaction product is obtained due to the fact that an inhibitor is present in the reaction. A reaction typically has a volume of between 5 and 100 μΐ, more preferred in range from 7 μΐ and 75 μΐ, most preferred in range from 10 μΐ and 50 μΐ, ideally in range from 15 μΐ and 25 μΐ. 
<!-- EPO <DP n="13"/>-->
 The inventors have found out, that between 100 and 5000 copies of the second nucleic acid (IC) are ideal. Preferably between 200 and 2000 copies are present, more preferably between 500 and 1500 copies, more preferably 1000 copies (+/- 20 %). The amount in μg/μl depends on the size/length of nucleic acid. Preferably the nucleic acid is a PCR product or plasmid DNA. </p><p id="p0052" num="0052">The invention also relates to a primer for amplifying the first nucleic acid (MCL) selected from the group of a. 5 -CCGGGAAGCAGAAGGTGG-3 <sup>'</sup> (SEQ ID NO. 12/4N-S1C Pr) b. 5 ' -Fam-CG AGCTC AGTTGTGCCTGTAGAGCTCG-dabcyl-C 18- ACCTCTTCCTCTTGGCTGGG-3 ' (SEQ ID NO. 1 1/4N-S 1 C) </p><p id="p0053" num="0053">The invention further relates to a primer pair for amplifying the first nucleic acid (MCL) consisting of the primers as follows: c. 5 '-CCGGGAAGCAGAAGGTGG-3 ' (SEQ ID NO. 12/4N-S 1 C Pr) d. 5 -Fam-CGAGCTCAGTTGTGCCTGTAGAGCTCG-dabcyl-C18- ACCTCTTCCTCTTGGCTGGG-3 ' (SEQ ID NO. 1 1/4N-S1C) </p><p id="p0054" num="0054">The invention further relates to a primer for amplifying the second nucleic acid (IC) selected from the group of e. 5 -GCTATCC AGTGTGCCTAGGC AA-3 ' (SEQ ID NO. 13/AT-IC_Rev.) f. 5 --YAK-</p><p id="p0055" num="0055">TGGCGTAGTCGTTCAACGCCA/Dabcyl/HEG/CCACGAGCGTACTTCGA CTGAA-3' (SEQ ID NO. 14/AT-IC_Yak) </p><p id="p0056" num="0056">The invention also relates to a primer pair for amplifying the second nucleic acid (IC) consisting of: g. 5 <sup>'</sup>-GCTATCCAGTGTGCCTAGGCAA-3 ' (SEQ ID NO. 13/AT-IC_Rev.) h. 5--YAK-</p><p id="p0057" num="0057">TGGCGTAGTCGTTCAACGCCA/Dabcyl/HEG/CCACGAGCGTACTTCGA CTGAA-3' (SEQ ID NO. 14/AT-IC Yak) 
<!-- EPO <DP n="14"/>-->
 The invention also relates to a primer for amplifying the third nucleic acid (MCL-Y) selected from the group of a. 5'- TGGCTGAGTTCCTCCACCTG-3 <sup>'</sup> (SEQ ID NO. 37 ; MCL-Y Pr) b. 5 '- Quasar670-cgaccgtgaagcatgcgtttcggtcg-BHQ2-C 18-agtgggagagctgggaa-3 <sup>'</sup> (SEQ ID NO. 38/MCL-Y Scorp) </p><p id="p0058" num="0058">Note, herein in all cases where a Scorpion primer is depicted (Scorp) as above for SEQ ID NO. 38 the priming part of the primer is the 3'-prime part and the invention relates in such a case preferably to this part and not the probe part (agtgggagagctgggaa-3 <sup>'</sup>). </p><p id="p0059" num="0059">Further, the invention relates to a kit for detecting and/or quantifying human nucleic acids, wherein the kit comprises one or more primers that, under stringent conditions, binds a sequence that shares at least 80 % sequence identity to a sequence according to SEQ ID NO. 1 over a stretch of 80 base pairs and, at least one primer or probe that stringently binds the second nucleic acid (IC), or comprises a primer or primer pair according to those outlined above. </p><p id="p0060" num="0060">Ideally, the kit has at least one primer that has a nucleotide sequence that differs from SEQ ID NO. 2, 3, 5, 6, 8, 9, 10, 1 1 and/or 12 and/or SEQ ID NO. 37 and/or 38 by no more than 5 nucleotides over a stretch of 18 nucleotides. Ideally, the kit has a nucleotide sequence that differs from SEQ ID NO. 2, 3, 5, 6, 8, 9, 10, 1 1 and/or 12 and/or SEQ ID NO. 37 and/or 38 by no more than 5 nucleotides over a stretch of 18 nucleotides </p><p id="p0061" num="0061">Figure Captions </p><p id="p0062" num="0062"> Fig. l </p><p id="p0063" num="0063">Figure 1 demonstrates the advantages of the invention by minimized reaction time. The "Qiagen Investigator Quantiplex" stands for a special embodiment of the method in scope of the invention. The first column (from left) shows the run time of the Qiagen Investigator Quantiplex" method on the Rotor-Gene Q real-time PCR instrument (Qiagen). Column 2 show the run time of the "Qiagen Investigator Quantiplex" method on the 7500 Fast PCR 
<!-- EPO <DP n="15"/>-->
 System from Applied Biosystems. For comparison, column 3 shows the run time for the Quantifiler Human Kit from Applied Biosystems, run on the 7500 Real-time PCR System from Applied Biosystems, column 4 shows the run time for the Quantifiler Duo Kit from Applied Biosystems run on the 7500 Real-time PCR System from Applied Biosystems, and column 5 shows the run time for the Plexor HY Kit from Promega, run on the 7500 Real-time PCR System from Applied Biosystems. </p><p id="p0064" num="0064">Fig. 2 Figure 2 shows a comparison of the accuracy of the different quantification methods in relation to the theoretical concentration. "Quantiplex Investigator" stands for a special embodiment of the method in scope of the invention. The commercially available quantification kits were set up and analyzed as described in the appropriate handbook. A serial dilution of human reference DNA (obtained from National Institute of Standards and Technology, USA) at known concentration was used as a template for all of the three kits. The "Quantiplex Investigator" method provides high accuracy to quantify all amounts of used template at their correct concentrations with a maximum error of 20%, especially the concentrations of 6,25 pg/μΐ and below were much more adequately quantified compared to the Quantifiler Human method (based on Quantifiler Human Kit from Applied Biosystems), which uses a single copy target, and the Plexor HY method (based on Plexor HY Kit from Promega), which uses a target present at few copies, reference given in description. Quantifiler Human method (based on Quantifiler Human Kit from Applied Biosystems which uses a single copy target) showed high fluctuations or even failed to generate a quantification result at and below 12,5 pg/μΐ human DNA. The Plexor HY shows high deviations from the theoretical quantification results. 2 μΐ of given dilutions of the human reference DNA were used in each reaction. Concentrations refer to the concentration in the template solution. NTC: no template control. </p><p id="p0065" num="0065">Fig. 3 </p><p id="p0066" num="0066">Figure 3 shows no copy-number variation of the human marker detected by SEQ ID NO. 1 1 and SEQ ID NO. 12 in genomic DNA samples from donors of different ethnic groups. A quantitative real-time PCR was run using to compare a human specific single-copy target and the Investigator Quantiplex multi-copy target. The ACT between the two targets is shown for 
<!-- EPO <DP n="16"/>-->
 the different populations. It becomes visible that the ACT is constant in all populations, demonstrating a constant copy number of the region detected by SEQ ID NO. 1 1 and SEQ ID NO. 12. Fig. 4 </p><p id="p0067" num="0067">Figure 4 shows the importance of high sensitivity and correct quantification (shown in Figure 2) by means of STR analysis following the quantification reaction. In Figure 4 the serial dilution of human DNA from Figure 2 was used to generate the shown STR profiles following the protocol for the Investigator ESSplex Kit (Qiagen). It demonstrates the possibility to obtain a complete STR profile even from the lowest concentration used in figure 2, demonstrating the usefulness of highly accurate quantification even of low template amounts. Fig. 5 </p><p id="p0068" num="0068">Figure 5 shows a dataset from the literature on the inhibition of the AmpFlSTR Identiler reaction by hematin, Using Identifiler (taken from the source indicated below -Quantifiler Human page 137) the DNA fingerprinting reaction works till a hematin concentration up to 20μΜ. </p><p id="p0069" num="0069">Source: </p><p id="p0070" num="0070">http://www3.appliedbiosystems.com/cms/groups/applied_markets_support/documents/general documents/cms_041395.pdf </p><p id="p0071" num="0071">Fig. 6 </p><p id="p0072" num="0072">Figure 6 shows a dataset from the literature on the inhibition of the AmpFlSTR NGM Kit. This is a so-called "next generation STR-Kits", which are much more resistant to the presence of inhibitors, in the example below up to 75μΜ hematin. </p><p id="p0073" num="0073">Source: </p><p id="p0074" num="0074">http://marketing.appliedbiosystems.com/images/All_Newsletters/Forensic_0710/pdfs/Custom er-Corner/nextGeneration.pdf 
<!-- EPO <DP n="17"/>-->
 Fig. 7 </p><p id="p0075" num="0075">Figure 7 shows an example of inhibitor sensitivity in quantification reactions. Data are taken from the developmental validation reports of the commercial kits Quantifiler Human and Y. Data are available in the validation report of the kit supplier, at: </p><p id="p0076" num="0076">Quantifiler Human </p><p id="p0077" num="0077">http://www3.appliedbiosystems.com/cms/groups/applied_markets_support/documents/general documents/cms_041395.pdf </p><p id="p0078" num="0078">Quantifiler Duo </p><p id="p0079" num="0079">http://www.appliedbiosystems.com.br/site/material/5q7aqqbm.pdf </p><p id="p0080" num="0080">The forensic workflow suggests the quantification of the DNA before the STR reaction is carried out. This is done to determine how much DNA was obtained from a sample, e.g. collected from a crime scene, and how much of this DNA should be used in a STR reaction. The typical STR reaction works optimally in certain range of template DNA and the whole analysis is very labor-intensive, therefore methodologies are needed that ensure a very high success rate in the STR analysis. Therefore, it is a real advantage if the quantification kit enables the user not only to surely identify the amount of DNA present but also to assess the absence of inhibitors, which could compromise the STR-reaction result, which would result in failure or loss of valuable sample material, which could be further purified in case critical inhibition is observed. </p><p id="p0081" num="0081">The data show that only the combined Quantifiler Human and Y kit show a slightly lower stability of the Internal Control target in comparison to the human target. In this case, the Ct value of the IC shifts to higher values when an inhibitor is contained in the DNA sample, while the Ct value of the Human and the Y kits remain stable, at least for smaller amounts of hematin. In the case of the Quantifiler human and Y Kits the resistance to inhibitors such as hematin is quite little (between 16μΜ and 20μΜ hematin in the reaction). Hence, methodologies are missing that are compatible with higher amounts of inhibitor resistance as required for the next generation of STR kits. 
<!-- EPO <DP n="18"/>-->
 Fig. 8 </p><p id="p0082" num="0082">Figure 8 shows an example of inhibitor sensitivity in quantification reactions. Data are taken from the developmental validation reports of the commercial kit Quantifiler Duo </p><p id="p0083" num="0083">Data are available in the validation report of the kit supplier, at: </p><p id="p0084" num="0084">Quantifiler Duo </p><p id="p0085" num="0085">http://www.appliedbiosystems.com.br/site/material/5q7aqqbm.pdf </p><p id="p0086" num="0086">The internal control system in the Quantifiler Duo Kit is more stable than the human specific target in the presence of inhibitors. The utility of the internal control system in this case is of course low because the internal control system doesn't give any indication of the presence of inhibitors in the sample while the DNA quantification is already compromised. In fact, the Ct values of the RPPHl and of the SRY systems shift to higher values even at low amounts of inhibitors. The dramatic increase of the Ct value of the RPPHl system to &gt;40 in the presence of 12,5 μΜ hematin makes the quantification of the human DNA impossible. </p><p id="p0087" num="0087"> The resistance to the presence of inhibitors in the sample is very low in comparison to the new generation STR-kits (i.e. 10 μΜ hematin and 3,75 ng/μΐ humic acid). </p><p id="p0088" num="0088">Fig. 9 </p><p id="p0089" num="0089">Figure 9 shows an example of inhibitor sensitivity in quantification reactions. Data are taken from the developmental validation reports of the commercial kit Plexor HY. Data are available in the validation report of the kit supplier, at: Plexor HY </p><p id="p0090" num="0090">http://www.promega.com/plexorhy/ an 157.pdf </p><p id="p0091" num="0091">The Plexor HY Kit shows quite the same stability of the Internal Control target in comparison to the human target, as visible by a comparable shift of the Ct to higher values for the autosomal target (upper panels) and the Internal control (IPC) shown in the lower panels. In this case, the Ct value of the IC shifts to higher values when an inhibitor is contained in the DNA sample. Even the Ct value of the human specific target shifts to higher levels when the inhibitor is contained in the sample, thus compromising the DNA quantification. In the case 
<!-- EPO <DP n="19"/>-->
 of the Plexor HY the resistance to inhibitors such as hematin is quite little (ca. 25 μΜ hematin in the reaction). </p><p id="p0092" num="0092">Fig. 10 </p><p id="p0093" num="0093">Figure 10 shows result of a reaction in scope of the invention in presence of the given concentrations of the PCR inhibitors Humic Acid and Hematin. </p><p id="p0094" num="0094"> Through the use of the invention a high stability of the internal control to higher concentrations of inhibitors and a higher stability of the human specific target could be achieved. This gives accurate quantification even if the internal control is completely inhibited. The inhibition of the human specific target starts at a concentration between 80 and 100 μΜ hematin, which perfectly fits the inhibitor resistance of the Next generation STR-Kits like AmpFlSTR NGM from Applied Biosystems or Investigator ESSplex from Qiagen. Fig. 11 </p><p id="p0095" num="0095">Shows the Sequence Listing Fig. 12 </p><p id="p0096" num="0096">Figure 12 shows a comparison of the accuracy of the different quantification methods in relation to the theoretical concentration. "Quantiplex Investigator HYres" stands for a special embodiment of the method in scope of the invention. The commercially available quantification kits were set up and analyzed as described in the appropriate handbook. A serial dilution of human DNAs (isolated from human blood from anonymous donors using the QIAamp Investigator Kit) and mixtures thereof at known concentrations was used as a template for all of the three kits. The "Quantiplex Investigator HYres" method provides high accuracy to quantify all amounts of used template at their correct concentrations, especially the concentrations of 6,25 pg/μΐ and below were much more adequately quantified compared to the Quantifier DUO method (based on Quantifier DUO Kit from Applied Biosystems), which uses a single copy target, and the Plexor HY method (based on Plexor HY Kit from Promega), which uses a target present at few copies, reference given in description. Quantifier DUO method (based on Quantifier DUO Kit from Applied Biosystems which uses a single copy target) showed high fluctuations or even failed to generate a quantification 
<!-- EPO <DP n="20"/>-->
 result at and below 1,5 pg/μΐ human DNA and failed to quantify male DNA concentrations below 1,5 pg/μΐ in the presence of female DNA background. The Plexor HY failed to quantify the male DNA fraction below 3 pg/μΐ in the presence or absence of background female DNA. 2 μΐ of given dilutions of the human reference DNA were used in each reaction. Concentrations refer to the concentration in the template solution. </p><p id="p0097" num="0097">Fig. 13 </p><p id="p0098" num="0098">Figure 13 shows the importance of high sensitivity and correct quantification (shown in Figure 12) by means of STR analysis following the quantification reaction. In Figure 13 the serial dilution of human DNA from Figure 12 was used to generate the shown STR profiles following the protocol for the Investigator ESSplex Plus Kit (Qiagen). It demonstrates the possibility to obtain a complete STR profile even from the lowest concentration used in figure 12, demonstrating the usefulness of highly accurate quantification even of low template amounts. </p><p id="p0099" num="0099">Fig. 14 </p><p id="p0100" num="0100">Figure 14 further demonstrates the advantages of the invention by minimized reaction time. The "QIAGEN Investigator Quantiplex HYres" stands for a special embodiment of the method in scope of the invention. The first column (from left) shows the run time of the QIAGEN Investigator Quantiplex HYres" method on the Rotor-Gene Q real-time PCR instrument (QIAGEN). Column 2 show the run time of the "QIAGEN Investigator Quantiplex HYres" method on the 7500 PCR System from Applied Biosystems. For comparison, column 3 shows the run time for the QIAGEN Investigator Quantiplex Kit form QIAGEN run on the Rotor-Gene Q real-time PCR instrument (QIAGEN), column 4 shows the run time for the QIAGEN Investigator Quantiplex Kit form QIAGEN run on the 7500 Real-time PCR System from Applied Biosystems, column 5 shows the run time for Quantifier Human Kit from Applied Biosystems, run on the 7500 Real-time PCR System from Applied Biosystems, column 6 shows the run time for the Quantifier Duo Kit from Applied Biosystems run on the 7500 Real-time PCR System from Applied Biosystems, and column 7 shows the run time for the Plexor HY Kit from Promega, run on the 7500 Real-time PCR System from Applied Biosystems. 
<!-- EPO <DP n="21"/>-->
 Fig. 15 </p><p id="p0101" num="0101">Figure 15 shows a result using the method of the invention. The method was applied in the presence of given concentrations of the PCR inhibitors Humic Acid and Hematin. </p><p id="p0102" num="0102">Using the invention a high stability of the internal control to higher concentrations of inhibitors and a higher stability of the human specific target could be achieved. This gives accurate quantification even if the internal control is completely inhibited. The inhibition of the human specific target starts at a concentration between 90 and 1 10 μΜ hematin, which perfectly fits the inhibitor resistance of the Next generation STR-Kits like AmpFlSTR NGM from Applied Biosystems or Investigator ESSplex from QIAGEN. </p><p id="p0103" num="0103">Fig. 16 Figure 16 shows Y-MC sequences, i.e. Y chromosome multi-copy sequences. SEQ ID NO. 15 serves as a reference sequence only. SEQ ID NOs. 15 to 35 may also be used. As outlined above, the method may also use only the Y chromosome sequences. </p><p id="p0104" num="0104">Examples </p><p id="p0105" num="0105">The quantification of human DNA is an essential step for the set-up of STR reactions in the forensic field. Many different kits are currently available on the market for quantifying DNA (Quantifiler Human, Quantifiler Y, Quantifiler Duo, Plexor HY), but all these kits have different disadvantages, such as the PCR product which is amplified on the human DNA is short and not representative for degraded DNA, the reaction is time-consuming, the chosen target is not stable in different populations or individuals. </p><p id="p0106" num="0106">The PCR product of the first nucleic acid is 146 bp. A reaction time of 48 minutes was achieved. This is in parts due to the fast PCR reaction chemistry with a pH range between 8 and 9 and containing NH<sub>4</sub><sup>+</sup>, K<sup>+</sup> and Mg<sup>2+</sup> ions and the presence of a fast hot start enzyme with a non-chemical hot-start method such as antibody, aptamer or affibodies, but also in particular to a stable multi-copy target providing higher sensitivity and reliability combined with an internal control which reports the presence of inhibitors, but still gives a good quantification result. This internal control has a stable Ct value over the whole DNA concentration range. 
<!-- EPO <DP n="22"/>-->
 The first and most surprising result is the high reaction speed due to the components of this invention. The combination of a fast non-chemical hot-start DNA polymerase, such as due to an antibody, aptamer or affibodies, a reaction buffer containing NH<sup>4+</sup>, K<sup>+</sup> and Mg<sup>2+</sup> ions, and the use of preferably also scorpion primers for detecting the multi-copy lead to this result. The reactions were carried out in a reaction buffer containing Tris-HCl, pH between 8.0 and 8.8, potassium salt, preferably chloride or sulfate, ammonium salt, preferably chloride or sulfate, magnesium chloride, each dNTP, 2.5 U of the indicated heat-stable DNA polymerase and 0.1 μΜ of each of the forward and reverse primers given in Table 1. </p><p id="p0107" num="0107">Table 1 Sequences </p><p id="p0108" num="0108"><img id="imgf000022_0001" he="56" wi="160" file="imgf000022_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0109" num="0109">The reaction chemistry also contained commercially available PEG-8000, a polyethylene glycol having a molecular weight of about 8000 Dalton. The reaction also contained Bovine Serum Albumine (BSA). </p><p id="p0110" num="0110">Other methods in the state of the art are much more time-consuming. One the other side, this combination allows for more sensitive and more reliable detection of the multi-copy target and hence a better quantification of the amount of DNA. The primers in Table 1 amplify a non-repetitive multi-copy target on the genome. The great advantage in using a multi-copy target is the high sensitivity, which can be achieved. The stability of this target region within different populations was also now shown in a multi-center study, where the copy number was measured for individuals belonging to different ethnic groups (see figure below). </p><p id="p0111" num="0111">It is important in the forensic field to have a quantification tool, which is very sensitive, and on the other hand, which shows a real negative signal in cases where no DNA is contained in 
<!-- EPO <DP n="23"/>-->
 the sample. After quantification using the Quantifier Human, no reliable quantification was possible under a concentration of 6,25 pg/μΐ. In this case, the user would not try to obtain the STR profile and classify the sample as "non-containing DNA" (Figure 2 below). Using the Plexor HY Kit there was little difference in the signal between low concentration samples and the NTCs. </p><p id="p0112" num="0112">Using the present invention the quantification in such a DNA concentration range is possible and even a full STR-profile can be obtained (Figure 3). This result shows that this reliable quantification has a better correlation to the expected result of the STR-profile. In fact, it helps not to miss any STR-profile using very low amounts of DNA and avoids analyzing a sample which definitely does not contain DNA. </p><p id="p0113" num="0113">The ideal internal control in DNA quantification for forensic applications is a PCR system which should indicate the presence of PCR inhibitors in the sample without compromising the quantification of the DNA. The quantification result should be as stable as possible, also in the presence of PCR inhibitors, in order to give the user the possibility to further make use of the quantification data for the DNA fingerprinting reaction set-up. </p><p id="p0114" num="0114">Using Identifiler the DNA fingerprinting reaction works until a hematin concentration of 20 μΜ is reached. </p><p id="p0115" num="0115">The so-called "next generation STR-Kits" are much more resistant to the presence of inhibitors, in the example below up to 75 μΜ hematin may be added. The typical forensic workflow suggests the quantification of the DNA before the STR reaction is carried out. This is done to determine how much DNA was obtained from a sample, e.g. collected from a crime scene, and how much of this DNA should be used in an STR reaction. The typical STR reaction works optimally in a certain range of template DNA and the analysis is very labor-intensive, therefore methodologies are needed that ensure a very high success rate. Therefore, it is a real advantage that the present invention enables the user not only to surely quantify the amount of DNA present but also to assess the absence of inhibitors, which could compromise the STR-reaction result, which would result in failure or loss of valuable sample material. 
<!-- EPO <DP n="24"/>-->
 Some examples of inhibitor sensitivity in quantification reactions are shown in the plots below. </p><p id="p0116" num="0116">Plexor HY may be found here: http://www.promega.com/plexorhy/anl 57.pdf. </p><p id="p0117" num="0117">Quantifier Human may be found here: </p><p id="p0118" num="0118">http://www3.appliedbiosystems.com/cms/groups/applied_markets_support/documents/general documents/cms_041395.pdf. Quantifier Duo may be found here: </p><p id="p0119" num="0119">http://www.appliedbiosystems.com.br/site/material/5q7aqqbm.pdf. </p><p id="p0120" num="0120">Only the combined Quantifier Human and Y kits show a slightly lower stability of the internal control target in comparison to the human target. In this case, the Ct value of the IC shifts to higher values when an inhibitor is contained in the DNA sample, while the Ct value of the Human and the Y kits remain stable, at least for smaller amounts of hematin. In the case of the Quantifier human and Y Kits the resistance to inhibitors such as hematin is quite little (between 16μΜ and 20μΜ hematin in the reaction). The internal control system in the Quantifier Duo Kit is more stable than the human specific target in the presence of inhibitors. The utility of the internal control system in this case is of course low because the internal control system does not give any indication of the presence of inhibitors in the sample while the DNA quantification is already compromised. In fact, the Ct values of the RPPHl and of the SRY systems shift to higher values even at low amounts of inhibitors. The dramatic increase of the Ct value of the RPPHl system to &gt;40 in the presence of 12,5 μΜ hematin makes the quantification of the human DNA impossible. </p><p id="p0121" num="0121">The resistance to the presence of inhibitors in the sample is very low in comparison to the new generation STR-kits (i.e. 10 μΜ hematin and 3,75 ng/μΐ humic acid). </p><p id="p0122" num="0122">The Plexor HY Kit shows quite the same stability of the internal control target in comparison to the human target. In this case, the Ct value of the IC shifts to higher values when an inhibitor is contained in the DNA sample. Even the Ct value of the human specific target shifts to higher levels when the inhibitor is contained in the sample, thus making correct DNA 
<!-- EPO <DP n="25"/>-->
 quantification difficult. In the case of the Plexor HY the resistance to inhibitors such as hematin is quite little (ca. 25 μΜ hematin in the reaction). </p><p id="p0123" num="0123">We could achieve a high stability of the internal control to high concentrations of inhibitors and a higher stability of the human specific target, which gives accurate quantification even if the internal control is completely inhibited. The inhibition of the human specific target starts at a concentration between 80 and 100 μΜ hematin, which perfectly fits the inhibitor resistance of the Next generation STR-Kits (such as the ABI NGM™ kit). It is known that real-time PCR is based on the real-time detection of the amplification of a PCR product. Actually, the length of this PCR product for DNA quantification purposes in forensic is very important. In fact, the quantification of DNA is the first step towards a DNA fingerprinting analysis, which is typically the analysis of short tandem repeats (STR). These repeats are analyzed in a multiplex-reaction where different loci are amplified through PCR in the same reaction well. The amplification product of these loci can vary from about 100 bp up to about 450 bp, depending on the loci, that have to be analyzed. </p><p id="p0124" num="0124">In the case of degraded DNA, which can occur for example when a stain has been exposed to stress factors such as light, the mean fragment length of the human DNA is reduced and often the longest loci are not amplifiable anymore. If the quantification assay detects shorter DNA fragments, it may overestimate the quantity of STR-sized fragments, resulting in a relatively high proportion of under-amplified and undetected STR alleles, which is an undesirable result. Therefore, we choose a longer fragment to be amplified for quantification purposes. 
</p></description><claims mxw-id="PCLM44727452" ref-ucid="WO-2012113577-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="26"/>-->CLAIMS </claim-statement><claim id="clm-0001" num="1"><claim-text>Method for quantifying and/or detecting one or more nucleic acids of a genome in a sample, wherein in an amplification reaction, </claim-text><claim-text> a. a first nucleic acid is amplified, the locus that is amplified is a multicopy locus (MCL) within the genome, wherein the locus shares at least 80 % sequence identity to a sequence according to SEQ ID NO. 1 over a stretch of 80 base pairs, and wherein, the multicopy locus has copies on at least two different chromosomes, </claim-text><claim-text> b. a second nucleic acid that has been added as an internal control (IC) is also amplified, </claim-text><claim-text> c. the amount of amplification product from the amplification of the first nucleic acid is determined. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>Method according to claim 1, wherein a third nucleic acid is additionally amplified, said locus is a multicopy locus (MCL-Y) on the human Y-chromosome, wherein the locus shares at least 80 % sequence identity to a sequence according to SEQ ID NO. 15 over a stretch of 80 base pairs, </claim-text><claim-text> a. the third nucleic acid that has been added as an internal control is amplified, and, </claim-text><claim-text> b. the amount of amplification product from the amplification of the first and the third nucleic acid is determined. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>Method according to claim 1 or 2, wherein also the amount of amplification product of the second nucleic acid is determined. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>Method according to claims 1 to 3, wherein the amplification method is a polymerase chain reaction or a real-time PCR reaction and the amount of nucleic acid determined, is determined either during the amplification process or as an end point measurement at the end of the amplification reaction. <!-- EPO <DP n="27"/>--> </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. Method according to any of the preceding claims, wherein the amplification product of the first nucleic acid (MCL) and/or third nucleic acid (MCL-Y) is between 60 base pairs and 200 base pairs long. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. Method according to any of the preceding claims, wherein the amplification product of the second nucleic acid (IC) is between 60 and 400 base pairs. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. Method according to claim 6, wherein the amplification product of the second nucleic acid (IC) is between 100 and 400 base pairs. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. Method according to any of the preceding claims, wherein the amplification of the second nucleic acid (IC) is longer than the amplification product of the first nucleic acid (MCL). </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. Method according to claims 1 to 7, wherein the amplification reaction comprises, a. Tris-HCl at a pH of between 8 and 8.8 and/or, </claim-text><claim-text> b. potassium salt selected from the group of, potassium chloride and potassium sulphate and/or, </claim-text><claim-text> c. an ammonium salt, preferably ammonium chloride or ammonium sulphate and/or, </claim-text><claim-text> d. magnesium chloride and/or, </claim-text><claim-text> e. a hot-start polymerase. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. Method according to any of the preceding claims, wherein the amplification reaction comprises, between 100 and 5000 copies of the second nucleic acid (IC). </claim-text></claim><claim id="clm-0011" num="11"><claim-text>1 1. Primer for amplifying the first nucleic acid (MCL) selected from the group of </claim-text><claim-text> a. 5 -CCGGGAAGCAGAAGGTGG-3 ' (SEQ ID NO. 12/4N-S 1 C Pr) </claim-text><claim-text> b. 5 -Fam-CGAGCTC AGTTGTGCCTGTAGAGCTCG-dabcyl-C 18- ACCTCTTCCTCTTGGCTGGG-3 <sup>'</sup> (SEQ ID NO. 1 1/4N-S1C). </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. Primer for amplifying the third nucleic acid (Y-MCL) selected from the group of </claim-text><claim-text> a. 5 <sup>'</sup>- TGGCTGAGTTCCTCCACCTG-3 <sup>'</sup> (SEQ ID NO. 37/MCL-Y Pr) <!-- EPO <DP n="28"/>--> b. 5 '-Quasar670-cgaccgtgaagcatgcgtttcggtcg-BHQ2-C 18-agtgggagagctgggaa-3 <sup>'</sup> (SEQ ID NO. 38/MCL-Y Scorp) </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. Primer pair for amplifying the first nucleic acid (MCL) consisting of the primers according to claim 1 1. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. Primer pair for amplifying the third nucleic acid (Y-MCL) consisting of the primers according to claim 12. </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. Primer for amplifying the second nucleic acid (IC) selected from the group of </claim-text><claim-text> a. 5 ' -GCTATCC AGTGTGCCTAGGC AA-3 (SEQ ID NO. 13/AT-IC_Rev.) b. 5 '-YAK-</claim-text><claim-text>TGGCGTAGTCGTTCAACGCCA/Dabcyl/HEG/CCACGAGCGTACTTCGA CTGAA-3 (SEQ ID NO. 14/AT-IC_Yak) </claim-text></claim><claim id="clm-0016" num="16"><claim-text>16. Primer pair for amplifying the second nucleic acid (IC) consisting of the primers according to claim 15. </claim-text></claim><claim id="clm-0017" num="17"><claim-text>17. Kit for detecting and/or quantifying human nucleic acids, wherein the kit comprises one or more primers that, under stringent conditions, binds a sequence that shares at least 80 % sequence identity to a sequence according to SEQ ID NO. 1 over a stretch of 80 base pairs and, at least one primer or probe that stringently binds the second nucleic acid (IC), or comprises a primer or primer pair according to claims 1 1 to 16, and optionally additionally, a primer, primer pair and/or probe that binds a sequence according to SEQ ID NO. 15 (MCL-Y) stringently. </claim-text></claim><claim id="clm-0018" num="18"><claim-text>18. Kit according to claim 17, wherein at least one primer in the kit has a nucleotide sequence that differs from SEQ ID NO. 2, 3, 5, 6, 8, 9, 10, 1 1 and/or 12 by no more than 5 nucleotides over a stretch of 18 nucleotides. </claim-text></claim><claim id="clm-0019" num="19"><claim-text>19. Method for quantifying and/or detecting one or more nucleic acids of a genome in a sample, wherein in an amplification reaction, </claim-text><claim-text> a. a first nucleic acid is amplified, the locus that is amplified is a multicopy locus on the Y chromosome (MCL) within the genome, wherein the locus shares at <!-- EPO <DP n="29"/>--> least 80 % sequence identity to a sequence according to SEQ ID NO. 15 over a stretch of 80 base pairs, </claim-text><claim-text>b. a second nucleic acid that has been added as an internal control (IC) is also amplified, </claim-text><claim-text>c. the amount of amplification product from the amplification of the first nucleic acid is determined. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
